Browse drugs

…, and 21% three biological drugs.Before starting treatment with tezepelumab, 89% of patients received oral corticosteroids (OCS) as mainten…

…7 (0.3); AER 3.9 (0.5).The mean changes (95% CI) in response to tezepelumab were as follows: total IgE 207.3 kU/L (49.9, 364.7) p<0.05, eos…

… patients were included (mean age 58.5±13.2 years; 62.7% male). Tezepelumab was used as first-line in 25/52 (48.1%), second-line in 15/52 (…

…nts to a novel anti-Thymic Stromal Lympopoetin (TSLP) biologic, Tezepelumab.Methods A retrospective, single-centre analysis was conducted o…

… treatment. Clinical trials demonstrated favourable efficacy of tezepelumab; real-world data are needed to explore effectiveness. This stud…

…on and Objectives In the phase 3 WAYPOINT study ( NCT04851964), tezepelumab demonstrated efficacy for the treatment of severe chronic rhino…

…tients with asthma, acting upstream in the inflammatory cascade.Tezepelumab, a monoclonal antibody that targets TSLP, has shown clinical ef…

…tober -2023 to September-2025) in patients with AS treated with tezepelumab. Variables: age, sex, asthma phenotype, forced expiratory volum…

…f individuals with SA continue to exacerbate frequently despite tezepelumab. Reduced efficacy in patients with lower baseline FeNO, child-o…

…hese data contribute to the growing evidence of the efficacy of tezepelumab in patients with CRS, including CRSwNP.…

…s with severe asthma achieved clinical remission by 52 weeks of tezepelumab treatment.…

…chieving clinical remission, demonstrating clinical benefits of Tezepelumab in managing severe asthma in routine care.…